Precision oncology ยท Tumor dormancy
Keeping cancer from reawakening.
MetaGuardTx is an early-stage therapeutics company developing a new approach to one of oncology's hardest problems: metastatic relapse. After treatment, residual cancer cells can lie dormant in distant organs for years before reawakening into overt disease. We intervene in the biology that governs that switch — to stop dormant cells from waking.
Focus
The dormancy switch
Targeting the biology that keeps disseminated cancer cells dormant, rather than chasing established tumors.
Window
Minimal residual disease
Engineered for the post-treatment period when relapse is being decided and remains preventable.
Stage
Founder-led, in formation
Building toward seed financing and proof-of-concept.
Investors and collaborators — let's talk.
Get in touch